NDA 020929 · Astrazeneca
Pulmicort Respules
Budesonide · Inhalation · Corticosteroid
Priority reviewLast checked: Nov 20, 2026Latest source record: Sep 6, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Aug 8, 2000
Approved uses
3
Original approval plus efficacy supplements
Registered trials
592
206 Phase 3, 32 recruiting
FAERS reports
42,547
32,411 serious, 3,177 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 11, 2019.
PULMICORT RESPULES ® is an inhaled corticosteroid indicated for: • Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age ( 1 ) Limitations of Use: Not indicated for the relief of acute bronchospasm ( 1 ) 1.1 Maintenance Treatment of Asthma PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Limitations of Use : • PULMICORT RESPULES is NOT indicated for the relief of acute bronchospasm.
Mechanism: Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. In standard in vitro and animal models, budesonide has approximately a 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical anti-inflammatory potency than cortisol (rat croton oil ear edema assay). As a measure of systemic activity, budesonide is 40 times more potent than cortisol when administered subcutaneously and 25 times more potent when administered orally in the rat thymus involution assay. The clinical significance of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 30, 2005 Supplement 22 · Efficacy Letter
- Feb 26, 2003 Supplement 13 · Efficacy LabelReviewLetter
- Aug 8, 2000 Original approval · Type 3 - New Dosage Form · priority review Pediatric Written RequestPediatric Amendment 1Pediatric Amendment 2
3 products under this application
- PULMICORT RESPULES · BUDESONIDE 1MG/2ML · SUSPENSION, INHALATION · Prescription · TE AN
- PULMICORT RESPULES · BUDESONIDE 0.25MG/2ML · SUSPENSION, INHALATION · Prescription · TE AN
- PULMICORT RESPULES · BUDESONIDE 0.5MG/2ML · SUSPENSION, INHALATION · Prescription · TE AN
Clinical trials
Interventional ClinicalTrials.gov studies with "Budesonide" as an intervention, any sponsor and status, largest first.
- A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and AdolescentsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01444430 · 12,460 participants · Start Dec 2011 · Primary completion Oct 2015
Drug: Symbicort pMDI; budesonide pMDI · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Anchorage, Alaska · 340 sites in all
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02465567 · 8,588 participants · Start Jun 30, 2015 · Primary completion Jul 26, 2019
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 741 sites in all
- Local Phase 4 Pan-European SMART StudyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00463866 · 8,424 participants · Start Mar 2007
Drug: Budesonide/formoterol · For: Asthma
Sites: Aalst, Belgium; Aarschot, Belgium; Aatrijken, Belgium · 817 sites in all
- Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild SymptomsPivotal-lookingStatus unknown
CardresearchAcademic, hospital or other
NCT04727424 · 7,819 participants (planned) · Start Jan 19, 2021 · Primary completion Jun 1, 2024
Drug: Budesonide Powder; Fluoxetine 20 MG and 1 more · For: Covid19; SARS-Associated Coronavirus
Sites: Belo Horizonte, Brazil; Betim, Brazil; Brumadinho, Brazil · 12 sites in all
- Inhaled Steroid Treatment as Regular Therapy in Early AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00641914 · 6,800 participants (planned) · Start Oct 1996 · Primary completion Feb 2003
Drug: budesonide; Placebo · For: Asthma
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06283966 · 5,250 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 3, 2027
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Athens, Alabama; Cullman, Alabama; Fairhope, Alabama · 922 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02224157 · 4,215 participants · Start Nov 28, 2014 · Primary completion Aug 16, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; budesonode bid + terbutaline 'as needed' · For: Asthma
Sites: Sydney, Australia; Botucatu, Brazil; Florianópolis, Brazil · 340 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02149199 · 3,850 participants · Start Jul 7, 2014 · Primary completion Aug 2, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; terbutaline 'as needed' + placebo budesonide bid and 1 more · For: Asthma
Sites: Bedford Park, Australia; Concord, Australia; Maroubra, Australia · 255 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,994
- dyspnoea4,876
- off label use4,639
- asthma3,791
- fatigue2,641
- condition aggravated2,522
- headache2,477
- diarrhoea2,412
- cough2,387
- pneumonia2,319
- nausea2,151
- wheezing2,124
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 161 |
| 2005 | 230 |
| 2006 | 219 |
| 2007 | 434 |
| 2008 | 576 |
| 2009 | 570 |
| 2010 | 549 |
| 2011 | 563 |
| 2012 | 822 |
| 2013 | 840 |
| 2014 | 1,041 |
| 2015 | 1,402 |
| 2016 | 1,632 |
| 2017 | 1,742 |
| 2018 | 2,306 |
| 2019 | 3,015 |
| 2020 | 3,624 |
| 2021 | 3,765 |
| 2022 | 4,013 |
| 2023 | 3,995 |
| 2024 | 4,143 |
| 2025 | 4,049 |
| 2026 | 2,856 |
Recalls
2 FDA enforcement reports for this application.
Jan 11, 2013 · Class III · Terminated
Does Not Meet Monograph: Budesonide may be slightly above or below the specification range.
Jan 11, 2013 · Class III · Terminated
Does Not Meet Monograph: Budesonide may be slightly above or below the specification range.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.
O'Byrne PM, FitzGerald JM, Bateman ED, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.
Bateman ED, Reddel HK, O'Byrne PM, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Beasley R, Holliday M, Reddel HK, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Budesonide nasal irrigation for chronic rhinosinusitis: a meta-analysis of therapeutic outcomes and safety profile.
Magboul N, Alharbi AF, Alqutub AT, et al. · Rhinology 2025 · Meta-Analysis, Systematic Review
- Budesonide treatment for microscopic colitis: systematic review and meta-analysis.
Sebastian S, Wilhelm A, Jessica L, et al. · Eur J Gastroenterol Hepatol 2019 · Meta-Analysis, Systematic Review
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.